Day 1 - Saturday, 2 March 2019
Meeting category
Date(s)
2 Mar 2019 - 3 Mar 2019
Location
Boston,
MA,
United States
Organizer
Titanium Level Support
Sponsor logos
International Workshop on HIV & Women 2019
Related Enduring Materials
Enduring Materials
Session 1: Current controversies for cART use in women of child bearing potential and in pregnancy -
Chairs
08:45 PDT
Clinical case: Researcher perspective
09:15 PDT
Clinical case: Community perspective
09:45 PDT
Clinical case: Policy implications
Abstract-driven Presentations - 11:15
11:15 PDT
INSTI exposure and neural tube defects – data from antiretroviral pregnancy registry
11:30 PDT
Congenital anomalies in infants of Canadian women exposed to antiretrovirals including dolutegravir
11:45 PDT
Evaluation of neural tube defects after exposure to Raltegravir during pregnancy
Hala Shamsuddin, MD
Merck, USA
12:00 PDT
Panel discussion: debaters, community, presenters
Session 2: New drug delivery systems, are they right for women? -
Chair
13:30 PDT
Invited lecture, focus on cabotegravir
14:00 PDT
Emerging drug delivery systems for treatment and prevention of HIV
Abstract-Driven Presentations - 14:30
14:30 PDT
Clinical development strategy to inform dosing of antiretroviral drugs in women: dolutegravir as a case study
14:45 PDT
HIV risk and characteristics of women seeking PrEP in a US demonstration project
Session 3: Unique challenges of growing up with HIV -
Chairs
15:45 PDT
Invited lecture: Unique challenges of growing up with HIV
Vanessa
CHIVA, UK
Abstract-driven presentations - 16:15
16:15 PDT
Optimizing HIV service delivery for young women who sell sex: a discrete choice experiment
Sue Napierala, PhD, MPH
RTI International, USA
16:30 PDT
High PrEP uptake among HIV-exposed women with pregnancy plans in South Africa
16:45 PDT
Innovative intervention for pregnant and breastfeeding adolescent mothers to enhance viral suppression in Homa Bay County, Kenya
Elizabeth Okoth (presented by N. Rakhmanina), MPH
Elizabeth Glaser Pediatric AIDS Foundation, Kenya
17:15 PDT
Poster viewing session 1
Guided poster tour 1: ARV and pregnancy issues
-
Altered levels of bioactive lipids in HIV and cART-exposed pregnancy
Kayode Balogun
Double-Dose Levonorgestrel Implant Does Not Fully Overcome Drug-Drug Interaction with Efavirenz
Kimbery Scarsi
Lopinavir (an HIV protease inhibitor) impairs uterine remodeling during pregnancy
Smriti Kala
Adverse pregnancy outcomes in HIV-positive pregnant women on ART in Kenya
Lisa Abuogi
Adoption of an HIV-neutral approach to pregnancy care in San Francisco, California
Dominika Seidman
Early antenatal care visit as it relates to prevention of mother to child transmission of HIV in sub-Saharan Africa
Adewale Adefila
Day 2 - Sunday, 3 March 2019
Session 4: Healthy aging with HIV for women -
Chair
08:30 PDT
Bone Health among women aging with HIV
09:00 PDT
Cardiac Muscle Health Among Women Aging with HIV
09:30 PDT
Important Drug- Drug interactions in Women aging with HIV
10:15 PDT
Poster viewing session 2
Guided poster tour 2: ARV in women
-
Efficacy of two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) versus dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral naïve women: GEMINI studies subgroup analysis
Romina Quercia
Tenofovir Alafenamide vs Tenofovir DF in women: pooled analysis of 7 clinical trials
Melanie Thompson
Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study
Peter Ackerman
Efficacy and Safety of the Once-daily Darunavir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ARTnaïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results
Aimee Wilkin
Guided poster tour 3: Comprehensive care in women
-
Prevalence of Cervical Dysplasia in HIV-positive Women Versus HIV-negative Women: The Case of Zambia
Aimee Rurangwa
Reflections on a specialist HIV menopause service
Roberta Brum
38% of child bearing women with HIV in the UK would like to breastfeed-Results from PACIFY study group
Farai Nyatsanza
Risk of hospitalisation according to gender and ethnicity among people living with HIV in the modern ART era
Sophia Rein
Depression symptom trajectories among mothers living with HIV in rural Uganda
Itziar Familiar
Development and piloting of a scale to measure trauma- and violence-aware principles of HIV care and practice for women living with HIV in Metro Vancouver, Canada
Kathleen Deering
Session 5: Research in women and HIV - 1 -
Chairs
11:30 PDT
Non-Vaccine Oncogenic HPV Persistence Among HPV-Vaccinated Women Living with HIV
11:45 PDT
Dolutegravir pharmacokinetics during pregnancy and postpartum
12:00 PDT
Intimate Partner Violence, Depression, and Mortality among a Cohort of Women living with HIV Marginalized by Socio-structural Inequities in Vancouver, Canada
Kalysha Closson
University Of British Columbia, Canada
12:15 PDT
Vaginal microbiome and associations with tenofovir diphosphate and lamivudine triphosphate in cervical tissues of Ugandan women
Session 6: HIV cure research - considerations for women -
Chair
13:30 PDT
HIV Cure: Where have we been, where are we going?
14:00 PDT
Invited lecture: Focus on women
Abstract-driven presentation - 14:30
14:30 PDT
Women’s involvement in clinical research: Women included in Dolutegravir clinical trials versus collaborative studies
Romina Quercia, MD, PhD, MPH
ViiV Healthcare, UK
Overview
Welcome
We would like to thank all 150 participants of the 9th edition of the International Workshop on HIV & Women (2 - 3 March 2019, Seattle, WA, USA) for their invaluable contribution in making this meeting such a success. The knowledge and life experiences shared in this workshop were incredibly valuable and will be cherished and put into good use.
On behalf of the Organizing Committee, we would also like to express our gratitude to ViiV Healthcare, Gilead, Janssen and Merck for their generous support.
Support
Endorsers
Media
Image
Language
Related Programs
